HI
SVA

Horizon Investments’s Sinovac Biotech, Ltd SVA Stock Holding History

Horizon Investments’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336 Sell
52
-52
-50% -$336 ﹤0.01% 1374
2026
Q1 		$673 Buy
104
+52
+100% +$337 ﹤0.01% 1341
2025
Q4 		$336 Hold
52
– – ﹤0.01% 1281
2025
Q3 		$336 Hold
52
– – ﹤0.01% 1155
2025
Q2 		$336 Buy
+52
New +$336 ﹤0.01% 1092
2024
Q4 		– Sell
-52
Closed -$336 – 936
2024
Q3 		$336 Hold
52
– – ﹤0.01% 825
2024
Q2 		$336 Hold
52
– – ﹤0.01% 812
2024
Q1 		$336 Hold
52
– – ﹤0.01% 796
2023
Q4 		$336 Hold
52
– – ﹤0.01% 785
2023
Q3 		$336 Hold
52
– – ﹤0.01% 743
2023
Q2 		$336 Buy
+52
New +$336 ﹤0.01% 718

Other funds holding SVA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Horizon Investments's SVA Position: Q2 2026 in Review

Horizon Investments reduced its Sinovac Biotech, Ltd (SVA) stake by 50% in Q2 2026, selling an estimated $336 and leaving 52 shares worth $336. The position accounts for ﹤0.01% of the portfolio, ranked #1374.

Horizon Investments first reported a position in SVA in Q2 2023 and has held it in 11 quarters since. The position peaked at $673 in Q1 2026. 28 funds tracked by Wall St. Rank hold SVA as of Q2 2026.

  • Horizon Investments held 52 shares of Sinovac Biotech, Ltd worth $336 as of Q2 2026.
  • Horizon Investments sold 52 Sinovac Biotech, Ltd shares in Q2 2026, an estimated $336.
  • Sinovac Biotech, Ltd made up ﹤0.01% of Horizon Investments's portfolio in Q2 2026, its #1374 holding.
  • Horizon Investments first reported a position in Sinovac Biotech, Ltd in Q2 2023 and has held it in 11 quarters since.
  • Horizon Investments's Sinovac Biotech, Ltd position peaked at $673 in Q1 2026.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2026.

Based on Horizon Investments's 13F filing for Q2 2026, filed 13 Aug 2026.